Comparative efficacy and safety of infliximab biosimilar (BCD-055) and innovator infliximab in patients with ankylosing spondylitis (results of international, multiple-center, double-blind phase I and phase III clinical studies)

This article presents results from two clinical trials of infliximab biosimilar, BCD-055, including comparative data on the pharmacokinetics (PK), efficacy and safety of BCD-055 and innovator infliximab (IFX) in patients with ankylosing spondylitis (AS).Objective: The purpose of phase I clinical stu...

Full description

Bibliographic Details

Published in:	Sovremennai͡a︡ revmatologii͡a Vol. 11; no. 3; pp. 14 - 25
Main Authors:	Karateev, D. E., Mazurov, V. I., Zonova, E. V., Nesmeyanova, O. B., Plaksina, T. V., Krechikova, D. G., Reshetko, O. V., Denisov, L. N., Gordeev, I. G., Pokrovskaya, T. G., Antipova, O. V., Kropotina, T. V., Povarova, T. V., Shesternya, P. A., Ushakova, E. N., Soroka, N. F., Pristrom, A. M., Eremeeva, A. V., Chernyaeva, E. V., Ivanov, R. A., Usacheva, U. V.
Format:	Journal Article
Language:	English
Published:	IMA-PRESS LLC 01-09-2017
Subjects:	ankylosing spondylitis bcd-055 biosimilar infliximab remicade
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!